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Abstract
Aim The aim was to explore the subjective health
expectations (sHE) of patients with Crohn’s disease
(CD) for both the near future and the elderly.
Method A cross-sectional survey was performed in four
gastroenterology centres in Hungary. Consecutive outpa-
tients with CD with age ≥ 18 were recruited. Socio-demo-
graphic and disease characteristics were recorded and the
Crohn’s Disease Activity Index (CDAI), Perianal Disease
Activity Index, Patients’ Global Assessment (PGA) and
current pain visual analogue scale (VAS) were assessed.
Subjective life expectancy (sLE) was explored and com-
pared to statistical life expectancy. Current health and sHE
for 1 year ahead and for ages 60/70/80/90 were assessed
using the descriptive system of the EQ-5D-3L.
Results In all, 206 patients (54.9% men) with a mean
age of 34.7 (SD 10.5 years) and disease duration of
10.5 (SD 6.3) years were studied. The CDAI score was
110.5 (SD 77.0) and 66% were treated by biologic
drugs. Mean current EQ-5D-3L score was 0.80 (SD
0.17) and patients expected a 0.05 (SD 0.15) improve-
ment within a year (P < 0.05). For ages 60/70/80/90,
a mean EQ-5D-3L score of 0.59, 0.38, 0.10 and
0.12 respectively was provisioned. Age, current health
status, sLE, PGA and pain VAS showed significant cor-
relation with both 1-year and older age sHE
(P < 0.05). Long-term sHE and sLE were negatively
affected by the presence of extraintestinal manifestations
but not by previous CD-related surgery.
Conclusion Patients with CD expect severe deteriora-
tion in health in later life. Given that unrealistic sHE
may affect patients’ current quality of life and health
behaviour, we encourage physicians to explore and con-
sider CD patients’ sHE in clinical care.
Keywords Crohn’s disease, expectations, life expec-
tancy, quality of life, EQ-5D-3L
What does this paper add to the literature?
• Thisis the first study to explore subjective health
expectations of patients with Crohn’s disease.
• Patientsexpect significant improvement in their health
within a year but severe deterioration in later life.
• Discussionsbetween patients and gastroenterologists
about evidence-based health expectations deserve more
attention in Crohn’s disease care.
Introduction
Crohn’s disease (CD) is a chronic inflammatory bowel
disease that may affect any part of the digestive track
causing abdominal pain and diarrhoea, and may lead to
functional disability and to life-threatening complica-
tions. Living with CD may cause a substantial burden
on patients due to alterations in their current health,
but not less importantly due to concerns and uncertain-
ties they may have regarding their future health [1].
Patients’ preferences and expectations regarding treat-
ments and healthcare have come into focus in the past
years [2–4]. However, still little is known about how
conscious CD patients are about the chronicity and
course of their disease and its impact on their future
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health, yet these can play a key role in their current life-
style and health-related decisions [5,6].
Brouwer and colleagues highlighted that individuals’
subjective health expectations (sHE) may differ from
objective measures and inaccurate subjective expecta-
tions regarding length and quality of life may have
important implications for health behaviour [7–9].
Those who underestimate their future health may place
less importance on seeking medical care and be less
compliant. In contrast, overestimation of future health
can influence negatively the perception of actual treat-
ment effects and may lead to dissatisfaction with care.
These issues are especially relevant and can be determin-
istic for successful care in chronic diseases, such as CD,
that require long-term care and compliance.
The aim of our study was therefore to explore CD
patients’ sHE regarding their health status 1 year ahead
and for ages 60, 70, 80 and 90, as well as their beliefs
on longevity. Secondarily, we aimed to analyse determi-
nants of sHE and compare CD patients’ results with
previous studies among the general public and other
chronic diseases.
Method
Study design
A cross-sectional survey was conducted at three aca-
demic gastroenterology departments and an inflamma-
tory bowel diseases centre in Hungary. Details of the
study have been described elsewhere [10,11]. In brief,
consecutive outpatients aged 18 years and over, with a
definitive diagnosis of CD, were invited to participate in
the study. Ethical approval for conducting the study
was granted by the National Scientific and Ethical Com-
mittee (reference no. 49548-4/2016/EKU) and the
study was performed in accordance with the ethical
standards laid down in the 1964 Declaration of Helsinki
and its later amendments or comparable ethical stan-
dards. Informed consent was signed by all patients. A
paper-based questionnaire survey was performed in
which patients were asked about their socio-demo-
graphic characteristics (self-reported sex, date of birth,
educational level, residence, employment status), CD-
related symptoms and health status. Gastroenterologists
provided data on patients’ medical history, clinical char-
acteristics, disease severity and treatments.
Measurement tools
Crohn’s Disease Activity Index (CDAI)
CDAI is a measure of disease activity in CD [12]. It
includes signs and symptoms based on the past 7 days,
and consists of eight components with a weight factor
attached to each. The total score is calculated by the
physician as a sum of items multiplied by weighting fac-
tors. Cut-offs for remission or low disease activity,
mildly active, moderately active and severely active dis-
ease are < 150, 150–219, 220–449 and 450–600,
respectively [13].
Perianal Disease Activity Index (PDAI)
The PDAI measures the severity of perianal fistulising
CD, covering five dimensions: fistula discharge, pain
and restriction of activities, sexual activity restriction,
type of perianal disease, and degree of induration [14].
Each dimension is scored on a scale between 0 (no
symptoms) and 4 (severe symptoms); the total PDAI
score is calculated as the sum of the items (range
between 0 and 20). PDAI ≤ 4 indicates inactive disease
while PDAI > 4 is considered as active disease [15].
Visual analogue scale (VAS)
The Patients’ Global Assessment VAS (PGA VAS) of 0–
100 with end-points defined as ‘not severe at all’ (0)
and ‘very severe’ (100) was applied to assess patients’
self-perceived severity of CD in general. CD-related cur-
rent pain and the worst experienced CD-related pain in
the past 3 months were measured separately with a 0–
100 VAS (pain VAS and worst pain VAS, respectively),
with end-points of ‘no pain at all’ (score 0) and ‘pain as
bad as it could be’ (score 100).
EQ-5D-3L questionnaire
The EQ-5D-3L is a generic health status measure con-
sisting of two parts [16,17]. The first part is a descriptive
system covering five dimensions of health: mobility, self-
care, usual activities, pain/discomfort and anxiety/de-
pression. Respondents are asked to indicate on a three-
level response scale (1 – no problem; 2 – some/moderate
problem; 3 – unable/extreme problem) for each dimen-
sion that best describes their current health status. Prefer-
ence weight (utility) originating from population-based
studies can be attached to each health state description.
Due to lack of country-specific tariffs in Hungary, the
value set of the UK by Dolan was used (score range from
0.549 to 1.0) [18]. The second part is a vertical 20 cm
visual analogue scale (EQ VAS) with end-points of 0
indicating the worst imaginable health status and 100
indicating the best imaginable health status.
Assessment of subjective expectations on future
health and longevity
Patients were asked to indicate on the descriptive system
of the EQ-5D-3L questionnaire the health status they
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expect to have a year later. To assess sHE for future
ages, we followed the same methodology that has been
successfully used in previous studies [7,8,19–22]
(Table S1). Patients were asked to indicate the level of
health problems they think they will have at ages 60,
70, 80 and 90 in the five dimensions of the EQ-5D-3L.
The EQ-5D-3L index scores for the subjectively
expected health states were calculated. Patients were
also asked to indicate the age to which they expected to
live (subjective life expectancy, sLE).
Statistical analysis
The difference between patients’ sLE and age- and sex-
matched statistical life expectancy was computed based
on data retrieved from the Hungarian Central Statistical
Office (latest available data: year 2016) [23]. The differ-
ences between expected (at year 1) and current EQ-5D-
3L index scores and between patients’ subjective and
statistical life expectancy were tested by Wilcoxon
signed-rank test. sHE across subgroups of patients were
compared by using the Mann–Whitney U test or
Kruskal–Wallis test, as appropriate. The relationship
between the continuous variables was analysed by Spear-
man’s correlations. A correlation coefficient of 0–0.19
was defined as very weak, 0.20–0.39 as weak, 0.40–0.59
as moderate, 0.60–0.79 as strong and 0.80–1 as a very
strong correlation. All the applied statistics were two-
sided with a significance level of P < 0.05. Statistical
analyses were performed with IBM SPSS version 25.0
(SPSS Inc., Chicago, Illinois, USA).
Results
Two hundred and six patients (54.9% men) with a mean
age of 34.7 (SD 10.5, range 18–70, median 34) years
participated in the survey. There were 31 patients in the
age group 45–54, but only seven patients in age group
55–64 and one aged over 65; therefore we joined these
three age groups for the analyses. Main clinical and
socio-demographic characteristics of the sample are pre-
sented in Table 1. The average disease duration was
10.5 (SD 6.3; N = 205) years, the mean CDAI score
was 110.5 (SD 77.0; N = 206) and the PDAI score
was 3.7 (SD 2.3; N = 83). The PGA, current and worst
pain in the past 3 months VAS scores were on average
50.1 (SD 23.9; N = 204), 24.7 (SD 23.9; N = 206)
and 42.0 (SD 31.4; N = 206), respectively. The major-
ity (75.7%) of the patients had low disease activity or
were in remission (CDAI < 150) and 66.0% were trea-
ted with a biologic drug at the time of the assessment:
infliximab 46.6%, adalimumab 17.5%, vedolizumab
1.9%. Current general health status as measured by the
EQ-5D-3L index was on average 0.8 (SD 0.17;
N = 203) and 72.7 (SD 19.7) on the EQ VAS.
Patients’ subjective health expectations for 1 year
ahead and for ages 60, 70, 80 and 90
Patients expected a modest improvement (mean 0.05,
SD 0.15, P < 0.05) in their health within a year on the
EQ-5D-3L index (Table 1). Women expected some-
what greater improvement than men but the provi-
sioned change was statistically significant in both
subgroups. The highest difference between the current
and expected EQ-5D-3L index score was observed in
age group 18–24 years.
Patients expected a significant worsening of their
health status with age achieving a mean score of 0.12
(SD 0.52) at age 90 (Table 1). The expected health sta-
tus for older ages did not differ significantly by sex,
educational level, clinical subtype (fistula), present treat-
ment type or by having had or not CD-related surgery
in the past. In contrast, the difference was statistically
significant across age groups for all the four future ages.
Those who had had extraintestinal manifestation
expected significantly worse health status for ages 60
and 70. We did not find a significant difference between
subgroups who expected or not to reach the specific
future ages in question.
Patients’ subjective expectations for longevity
The main findings are presented in Table 2. Patients
with CD expected to live up to 76.8 (SD 3.5; range
40–100) years of age on average. Women and patients
in age group 35–44 expected on average 3.0 (SD 12.0)
and 4.2 (SD 10.6) years shorter life than their sex- and
age-matched statistical life expectancy, respectively. Sig-
nificant but weak negative correlations were found
between sLE and current general health and pain (EQ-
5D-3L, PGA VAS, pain VAS), but not with the disease-
specific CDAI and PDAI scores. Correlations between
sLE and sHE for 1-year ahead and for future ages were
weak and moderate, respectively (Table 3).
Correlations between subjective health expectations
and patient characteristics
Results are presented in Table 3. With regard to sHE in
1 year’s time, we found that patients who were
younger, had shorter disease duration and better gen-
eral health status (EQ-5D-3L) expected to have a sig-
nificantly better EQ-5D-3L index score. Stronger CD-
related pain (currently and in the past 3 months) nega-
tively influenced the expected EQ-5D-3L score for
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1 year ahead. (Correlations were moderate or weak.)
The relationship was not significant with either the
CDAI or the PDAI scores. Our findings with respect to
sHE at ages 60, 70, 80 and 90 were very similar, with a
few exceptions (Table 3).
Discussion and conclusions
In this empirical study we surveyed the sHE of adult
CD patients attending for outpatient care at gastroen-
terology departments. Patients’ current general health
status was somewhat worse than that of the general
population in Hungary (mean EQ-5D-3L index score
of 0.80 at a mean age of 34.7 years vs 0.86 in age
group 35–44 years) [24]. Patients expected on aver-
age a statistically significant improvement in their gen-
eral health status (0.05-point increase on the EQ-5D-
3L) within a year. To the best of our knowledge, a
minimum clinically important difference for the EQ-
5D-3L index score has not been established in CD,
yet [25]. Nonetheless, we think this result indicates
that patients expect rather a stability (non-worsening)
and maybe some improvement of their disease in the
near future.
Table 1 Patients’ actual health-related quality of life and subjective expectations for the future (mean, SD)
N (%)
Current
EQ-5D-3L
index
score
Expected
EQ-5D-3L
index
score for
1 year ahead
Difference
between
expected
(at year 1)
and current
EQ-5D-3L
index scores
Expected EQ-5D-3L index scores at age
60 years 70 years 80 years 90 years
N (response
rate, %)
203 (98.5) 202 (98.1) 199 (96.6) 193 (93.7) 193 (93.7) 185 (89.8) 180 (87.4)
Total sample 206 0.80 (0.17) 0.85 (0.17) 0.05 (0.15)* 0.59 (0.40) 0.38 (0.49) 0.10 (0.53) –0.12 (0.52)
Sex Female 93 (45.1) 0.79 (0.17) 0.84 (0.19) 0.06 (0.17)* 0.63 (0.39) 0.42 (0.49) 0.12 (0.55) –0.10 (0.54)
Male 113 (54.9) 0.81 (0.17) 0.86 (0.15) 0.04 (0.14)* 0.56 (0.41) 0.34 (0.5) 0.08 (0.51) –0.13 (0.51)
Age groups 18–24 37 (18) 0.83 (0.16) 0.94 (0.11)† 0.11 (0.13)* 0.76 (0.26)† 0.61 (0.39)† 0.38 (0.42)† 0.18 (0.5)†
25–34 71 (34.5) 0.82 (0.17) 0.9 (0.13)† 0.08 (0.15)* 0.59 (0.4)† 0.38 (0.47)† 0.03 (0.53)† –0.18 (0.49)†
35–44 59 (28.6) 0.77 (0.19) 0.81 (0.19)† 0.04 (0.17) 0.46 (0.48)† 0.27 (0.53)† –0.10 (0.57)† –0.18 (0.56)†
45– 39 (18.9) 0.78 (0.15) 0.75 (0.19)† –0.03 (0.12) 0.66 (0.37)† 0.31 (0.52)† 0.12 (0.48)† –0.21 (0.44)†
Education
(missing n = 1)
Lower 14 (6.8) 0.72 (0.18) 0.77 (0.14)† 0.04 (0.14) 0.58 (0.51) 0.47 (0.43) 0.08 (0.53) –0.24 (0.47)
Secondary 132 (64.4) 0.80 (0.18) 0.84 (0.18)† 0.04 (0.15)* 0.58 (0.39) 0.34 (0.52) 0.10 (0.54) –0.09 (0.53)
College/
university
59 (28.8) 0.82 (0.16) 0.89 (0.13)† 0.08 (0.16)* 0.63 (0.39) 0.46 (0.44) 0.10 (0.51) –0.13 (0.51)
Fistula‡ No 122 (59.2) 0.79 (0.17) 0.86 (0.15) 0.07 (0.15)* 0.55 (0.44) 0.35 (0.51) 0.06 (0.54) –0.15 (0.52)
Yes 84 (40.8) 0.81 (0.17) 0.85 (0.19) 0.03 (0.15)* 0.66 (0.33) 0.42 (0.47) 0.15 (0.51) –0.07 (0.51)
Extraintestinal
manifestations‡
(missing n = 1)
No 79 (38.5) 0.85 (0.14)† 0.91 (0.13) 0.05 (0.11)* 0.69 (0.35)† 0.47 (0.46)† 0.19 (0.51) –0.05 (0.52)
Yes 126 (61.5) 0.76 (0.18)† 0.82 (0.18)† 0.05 (0.17)* 0.54 (0.43)† 0.32 (0.53)† 0.04 (0.53) –0.16 (0.51)
Previous surgery None 87 (42.2) 0.81 (0.17) 0.86 (0.17) 0.05 (0.16)* 0.63 (0.37) 0.36 (0.49) 0.09 (0.5) –0.12 (0.49)
Resection 33 (16) 0.82 (0.18) 0.83 (0.2) 0.01 (0.1) 0.62 (0.41) 0.48 (0.49) 0.18 (0.53) –0.15 (0.53)
Non-resection 53 (25.7) 0.80 (0.17) 0.86 (0.16) 0.07 (0.14)* 0.58 (0.42) 0.37 (0.5) 0.08 (0.57) –0.10 (0.57)
Both 33 (16) 0.76 (0.18) 0.84 (0.13) 0.07 (0.18)* 0.5 (0.47) 0.32 (0.5) 0.05 (0.56) –0.12 (0.55)
Present
treatment§
Systemic
non-biologic
67 (32.5) 0.76 (0.19) 0.84 (0.17) 0.08 (0.19)* 0.60 (0.41) 0.42 (0.47) 0.13 (0.51) –0.11 (0.48)
Biologic 136 (66.0) 0.82 (0.16) 0.86 (0.17) 0.04 (0.13)* 0.59 (0.41) 0.36 (0.51) 0.08 (0.54) –0.12 (0.54)
Expected
survivors¶
Expected
survivors
N/A N/A N/A N/A 0.62 (0.38) 0.51 (0.41) 0.34 (0.48) 0.45 (0.38)
Expected
non-survivors
N/A N/A N/A N/A 0.00 (0.57) 0.01 (0.54) –0.1 (0.48) –0.23 (0.47)
In age group 45–54, mean (SD) EQ-5D-3L scores were currently 0.77 (0.14); expected for 1 year ahead 0.74 (0.19); for age 60,
0.63 (0.40); for age 70, 0.27 (0.51); for age 80, 0.08 (0.47); for age 90, 0.22 (0.44).
*Wilcoxon signed-rank test P < 0.05.
†Mann–Whitney U test or Kruskal–Wallis test P < 0.05.
‡Symptom occurred either in the patient’s history or was present at the time of the survey.
§There were three patients who did not get any treatment.
¶Expected to live until the future age asked.
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In contrast, CD patients provisioned a sharp deterio-
ration of health in their older age (Table 1). CD
patients expected to have worse health status than the
general population at these ages (Fig. 1). The gap
between short-term and long-term sHE suggests that
CD patients attending gastroenterology care are rather
optimistic regarding their health in the immediate
future but they have serious concerns about their
chances to have well-controlled disease over a lifetime.
Qualitative studies are suggested to explore the underly-
ing causes, including medical, social (access, affordabil-
ity) and patient-related reasons [26,27]. Clinicians
should make efforts to explore patients’ sHE and help
them to put their sHE on a realistic perspective based
on the available evidence. On the one hand, overestima-
tion of short-term treatment effects may lead to
disappointments regarding the results achieved and may
induce feelings of inadequacy and lead to worsening of
compliance. On the other hand, a pessimistic vision
about the distant future is probably an unfounded extra
burden and avoidable harm on most CD patients.
Our analyses revealed that age, disease duration, self-
reported current health (EQ-5D-3L) and pain measures
correlated significantly with 1-year sHE but disease
activity measures (CDAI, PDAI) did not (Table 3).
Current health correlated significantly also with sHE for
ages 60, 70 and 80. Hence applying these patient-re-
ported outcomes alongside the standard medical deci-
sion making tools (CDAI and PDAI) is strongly
suggested as these carry valuable information not only
about patients’ current self-perceived status but also
about their beliefs on health perspectives.
Table 2 Subjective and age- and sex-matched statistical life expectancy
Variables Subgroups N (%)
Statistical life
expectancy
(years), N = 206
Subjective life
expectancy
(years),
N = 194
Difference
between
statistical and
subjective life
expectancy
(years), N = 194
Wilcoxon
signed-rank
test P
Total sample – 206 76.8 (3.5) 75.9 (11.5) 0.95 (11.6) 0.2174
Sex Female 93 (45.1) 80.5 (1.1) 77.4 (12.0) 3.0 (12.0)* 0.0153
Male 113 (54.9) 73.7 (0.7) 74.6 (11.1) 0.9 (11.1) 0.7063
Age groups 18–24 37 (18) 76.6 (3.6) 78.0 (12.1) 1.3 (11.9) 0.4559
25–34 71 (34.5) 75.7 (3.2) 75.2 (11.9) 0.5 (12.3) 0.9033
35–44 59 (28.6) 77.3 (3.4) 73.1 (10.6) 4.2 (10.6)* 0.0037
45– 39 (18.9) 78.2 (3.7) 79.9 (10.5) 1.3 (11.1) 0.7934
Education
(missing n = 1)
Lower 14 (6.8) 76.3 (3.5) 72.6 (13.5) 3.9 (12.2) 0.4628
Secondary 132 (64.4) 76.8 (3.5) 75.6 (11.6) 1.3 (11.9) 0.1709
College/university 59 (28.8) 77.0 (3.6) 77.7 (10.7) 0.7 (10.9) 0.7145
Fistula No 122 (59.2) 76.5 (3.4) 74.8 (11.5) 1.8 (11.5) 0.1054
Yes 84 (40.8) 77.1 (3.6) 77.7 (11.4) 0.4 (11.8) 0.9794
Extraintestinal
manifestations
No 149 (72.3) 76.5 (3.5) 76.8 (11.9) 0.2 (12.0) 0.8850
Yes 57 (27.7) 77.4 (3.5) 73.5 (10.1) 4.2 (9.9)* 0.0069
Previous surgeries None 87 (42.2) 76.8 (3.5) 78.0 (11.7) 1.1 (12.1) 0.5707
Resection 33 (16) 77.2 (3.8) 77.3 (10.7) 0.1 (10.5) 0.7761
Non-resection 53 (25.7) 76.4 (3.5) 73.7 (11.0) 2.8 (10.8) 0.0504
Both 33 (16) 76.9 (3.3) 72.6 (11.9) 4.3 (12.2) 0.0649
Present treatment None 3 (1.5) 78.3 (3.8) 70.0 (13.2) 8.3 (13.0) 0.2851
Systemic non-biologic 67 (32.5) 76.6 (3.5) 75.7 (10.2) 1.2 (11.3) 0.5432
Biologic 136 (66) 76.8 (3.5) 76.2 (12.1) 0.7 (11.8) 0.4139
Disease activity groups CDAI < 150 156 (75.7) 76.72 (3.54) 76.12 (11.37) 0.69 (11.43) 0.2817
CDAI 150–219 32 (15.5) 76.03 (3.38) 77.45 (10.57) 1.14 (10.11) 0.5240
CDAI 220 ≥ 18 (8.7) 78.50 (2.81) 72.06 (13.92) 6.44 (14.37) 0.109
Retired due to
Crohn’s disease
Yes 47 (22.8) 77.60 (3.48) 72.41 (11.46) 5.27 (11.24) 0.0061
No 159 (77.2) 76.52 (3.47) 76.97 (11.36) 0.31 (11.48) 0.9575
Stoma Yes 10 (4.9) 76.30 (3.43) 72.10 (9.46) 4.20 (10.56) 0.3270
No 196 (95.1) 76.79 (3.50) 76.15 (11.60) 0.78 (11.69) 0.3271
*P < 0.05.
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Most of the patients did not expect significant short-
ening of their life due to CD although an increased
standardized mortality ratio may occur, especially in
specific subgroups with CD [28]. sLE showed signifi-
cant correlations with sHE. Therefore, it is strongly
suggested to explore these two in parallel.
Comparisons with some previous studies deserve
mentioning. sHE for future ages were explored in two
online surveys among the general population in Hun-
gary [19,29]. Both confirmed that people in general
expect health deterioration with age and the expected
health status is worse than the actual health status of
the general public from age 70 and above. The same
pattern was observed among the general population in
the Netherlands [7]. Two separate studies in Hungary
involving patients with rheumatoid arthritis and psoria-
sis reported very similar findings to ours in CD [20,21]
(Fig. 1). It seems that, despite the incredible develop-
ment that health professionals have witnessed in the
past two decades in the treatment of inflammatory dis-
eases in rheumatology, dermatology and gastroenterol-
ogy, many patients still have little confidence in having
good health in old age. Another similarity is that
rheumatoid arthritis patients expected a robust improve-
ment in health in the short term at the initiation of
their first biologic treatment. Nonetheless, it was proved
to be an overestimation based on the measurements at
the follow-up visit [20]. Hence we think that more
attention should be paid to informing patients about
the awaited size, timing and character of the treatment
effects, as well as about long-term effects of adequate
care. To the best of our knowledge, similar studies have
not been performed for inflammatory bowel disease
patients.
Some limitations of our study deserve mentioning
and we would like to suggest a few directions for fur-
ther research. Patients in remission and with mildly
active disease were overrepresented in the sample while
only few patients aged 55 and over participated in the
study. Given the cross-sectional design we could not
match sHE to measured data. Therefore, we suggest
testing the results of this explorative research in larger
prospective studies involving representative patient sam-
ples and analysing the determinants of sHE. It is rec-
ommended to record response rate (which we have
omitted) in order to assess potential non-response bias.
Table 3 Spearman’s correlations between subjective health expectations and continuous variables
Variables
Expected EQ-5D-3L
index score in 1 year
Expected EQ-5D-3L index score at the age
of . . . Expected length of life
EQ-5D-3L
index score
in 1 year
Difference
expected
(in 1 year) –
current 60 years 70 years 80 years 90 years
Subjective
LE
Difference
statistical –
subjective LE
Age (years) 0.421* 0.341* 0.17 0.267* 0.191* 0.231* 0.039 0.137
Disease duration (years) 0.198* 0.201* 0.127 0.162* 0.14 0.129 0.09 0.135
EQ-5D-3L (0.549–1) 0.664* 0.289* 0.572* 0.504* 0.424* 0.292* 0.307* 0.333*
EQ VAS (0–100) 0.428* 0.135 0.333* 0.354* 0.326* 0.238* 0.23* 0.252*
CDAI (0–600) 0.049 0.139* 0.029 0.116 0.103 0.038 0.02 0.004
PDAI (0–20) 0.066 0.137 0.039 0.175 0.088 0.154 0.21 0.14
Patient’s Global
Assessment VAS
(0–100)
0.305* 0.067 0.280* 0.259* 0.257* 0.173* 0.143* 0.163*
Current pain VAS (0–100) 0.376* 0.137 0.297* 0.188* 0.151* 0.073 0.170* 0.236*
Worst pain VAS in
the past 3 months
(0–100)
0.300* 0.188* 0.255* 0.174* 0.183* 0.79 0.180* 0.235*
Subjective life
expectancy (years)
0.242* 0.049 0.592* 0.523* 0.535* 0.519* – -0.941*
Statistical life
expectancy (years)
0.185* 0.092 0.019 0.041 0.031 0.082 0.099 0.208*
CDAI, Crohn’s Disease Activity Index; EQ VAS, is a vertical 20 cm visual analogue scale with endpoints of 0 indicating the worst
imaginable health state and 100 indicating the best imaginable health state; LE, life expectancy; PDAI, Perianal Disease Activity
Index; VAS, visual analogue scale.
*Spearman’s rho P < 0.05.
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We suggest considering the use of the EQ-5D-5L ver-
sion (with five-level response scale) to explore sHE in
future studies [30]. The EQ-5D-5L has been proved to
have better measurement properties as a health status
measure than the EQ-5D-3L [10], and we expect an
increase in its use in CD registries and clinical studies.
We used the tariffs of the UK to calculate actual and
expected EQ-5D-3L scores due to lack of local tariffs at
the time of the analyses. These tariffs may differ signifi-
cantly across countries [31], and indeed, according to
our preliminary analyses using the recently published
country-specific tariffs for Hungary [32] we found
somewhat different scores (slightly lower average score
for current status and higher for 1 year ahead, and it
was decreasing for future ages but at varying degrees;
data not shown). For comparability reasons, we stayed
with the UK value set in this current study. It would be
useful also to investigate the potential disagreements
between patients’ and clinicians’ views. Patients’ sHE
regarding treatment effects may change with the
number of therapy failures and thus influence the evalu-
ation of subsequent treatments. Influencing factors of
sHE have only been partly identified in our study; fur-
ther research (on health literacy, personality traits, cul-
tural characteristics, availability of health and social care
support) is recommended.
In conclusion, our study suggests that CD patients
attending gastroenterology care expect health improve-
ment in the near future but a severe health deteriora-
tion in later life. Patients’ age, current general health
status and pain seem to have a significant impact on
sHE, but clinical history and current treatment might
have substantial influence as well. We believe that our
research has opened valuable new doors in the care of
CD patients and hope it will inspire new sHE studies.
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